The European Patent Office (EPO) has published patent application EP4626885A1, filed by Janssen Pharmaceutica NV, concerning novel bicyclic compounds. The patent application, specifically related to organic chemistry (C07D), describes cyclobutyl substituted bicyclic compounds and lists potential therapeutic applications, including the treatment of specific types of cancer (A61P 35/02).

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and legal professionals involved in intellectual property, drug development, and competitive landscape analysis within the European Union. The patent is designated for multiple European states, indicating its broad territorial scope within the EU.